Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q4 2017 · 10-K
Revenue$9.80M$9.80M−56.7% vs Q4 2016 Net Income-$88.29M-$88.29MderivedN/M vs Q4 2016 EPS Diluted-$1.81-$1.81N/M vs Q4 2016 Operating Income-$90,130,000
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
N/M
Operating Cash Flowderived-$74,454,000N/M Free Cash Flowderived-$75,734,000N/M Margins · derivedOperating margin-919.8%−666.3 pt vs Q4 2016
Net margin-901.0%−798.5 pt vs Q4 2016
ended Dec 31, 2017 · filed Feb 14, 2018 · 45 d after period end